GPT and COVID-19: Liver co-morbidities are known in around 2–11% of COVID-19 patients, where dysregulated levels of alanine amino transferase (ALT) and aspartate amino transferase (AST) have been reported in some 14–35% of cases, coinciding with disease progression [102,103,104].